Page 7 of 8: studies 121 to 140 of 151, newest first. Back to the MDMA overview
The British Journal of Psychiatry February 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Scientific Reports February 10, 2026 Michelle Olofsson, Kasim Acar, Otto Simonsson et al.
Recent research has highlighted the potential of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for the treatment of post-traumatic stress disorder and other trauma-related psychiatric conditions. However, less is known about the effects of MDMA use on psychological well-being in populations with trauma histories outside of clinical contexts. In the present study, we assessed...
Behavioural Brain Research February 10, 2026 Kristin A. Felsch, Jessica A. Siegel
3,4-methylenedioxymethamphetamine (MDMA) is a psychomotor stimulant drug. While much research has examined the effects of MDMA in adults, relatively little research has examined the effects in adolescents. Adolescence is a unique period of brain development, and the effects of MDMA may differ in adolescents compared to adults. In this review, we summarize the literature on the effects of acute...
International Journal of Electrochemical Science February 9, 2026 Anne Felim, Anne Neudörffer, François P. Monnet et al.
A straightforward one-pot electrochemical synthesis of bis-catechol-thioether metabolites of MDMA (ecstasy), 2,5-bis(glutathion-S-yl)-N-methyl-α-methyldopamine and 2,5-bis(N-acetylcystein-S-yl)-N-methyl-α-methyldopamine, in acceptable yields and high degree of purity (99%), is described under environmentally friendly conditions. The undeniable benefits of this method, which uses...
Pharmacopsychiatry February 5, 2026 Tianyi Xu, Sabrina Wong, Gia Han Le et al.
Serotonergic psychedelics, such as lysergic acid diethylamide, and psilocybin, and the entactogen 3,4-methylenedioxymethamphetamine exhibit agonist activity at the 5-hydroxytryptamine 2B receptor, a signalling pathway known to mechanistically mediate drug-induced valvular heart disease. This systematic review evaluates whether chronic or repeated use of psychedelics and...
Biological Psychiatry February 3, 2026 Mehmet Bostancıklıoğlu, Davut Sinan Kaplan, Ramazan Bal et al.
Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); however, the underlying cellular mechanisms remain incompletely understood. This study investigated whether adult myelin plasticity contributes to the therapeutic actions of psilocybin and MDMA in a rat model of contextual fear conditioning. Adult male...
Neuropsychopharmacology February 2, 2026 Maya C Gaines-Smith, Justin M Silverman, Michael Fiorillo et al. 3 citations
The psychoactive entactogen 3,4-methylenedioxymethamphetamine (MDMA), widely known as a recreational drug, is gaining renewed attention as a potential psychotherapeutic adjunct for treatment-resistant psychiatric disorders, yet its neurobiological mechanisms - particularly those related to its stereoisomers and sex-specific effects - remain poorly understood. Here, we report stereoselective and...
Journal of Affective Disorders February 2, 2026 Alene Sze Jing Yong, Aimee Freeburn, Suzie Bratuskins et al.
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic stress disorder (PTSD) outside of clinical trials. This study explored the direct experience of Australian clinicians, researchers, and patients regarding the use of MDMA-assisted psychotherapy (MDMA-AP) for PTSD to inform guideline development....
Psychopharmacology February 1, 2026 Ana Deutsch, Connor J Haggarty, Gavin N Petrie et al. 1 citation
Stimulant drugs such as methamphetamine (MA) and 3,4-methylenedioxymethamphetamine (MDMA) can impact neurobiological systems implicated in stress, reward processing, and drug use. Although recent preclinical evidence implicates the endocannabinoid (eCB) system in these processes, little is known about the acute effects of stimulants on eCB levels in humans. The aim of the present study was to...
Pharmacology, Biochemistry, and Behavior February 1, 2026 Daniel A Palacios-Lagunas, Juan C Hernández-mondragón, Kjell Fuxé et al. 1 citation
The promotion of prosocial behavior is a remarkable MDMA property. Such an effect is rather uncommon among other psychoactive substances and has been proposed to be of relevance for the potential therapeutic utility of MDMA. We aim to expand our knowledge of the prosocial effects of MDMA, considering sex and housing conditions as extra variables. To this end, housed individually or...
Neurologic Clinics February 1, 2026 Mina Ansari, Sophie I Elliott, Sophie E Holmes et al. 1 citation
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...
January 30, 2026 Makaela Weeda, Valeria Gazzola, Christian Keysers et al. preprint
Besides its widespread recreational use, MDMA attracted the attention of many researchers and clinicians for its therapeutic potential for various mental disorders. Although recent clinical studies yielded promising results, MDMA has not been approved for medical use, partially due to the lack of clear insight into its neurobiological effects. In fact, although some suggest that MDMA’s...
Journal of Clinical Epidemiology January 23, 2026 Marija Franka Žuljević, Antonija Mijatović, Renata Orhanović et al. 4 citations
MDMA and psilocybin are being investigated as potential treatments for psychiatric disorders and have received increasing regulatory and media attention, due to the methodological complexities and societal context of psychedelic substances. Therefore, we assessed the consistency of protocol registration and adverse event (AE) reporting in clinical trials of MDMA and psilocybin. We conducted a...
BMC Psychology January 21, 2026 Christina Chwyl, Angelica Spata, Will Lucas et al.
Findings indicate a "mindset-over-molecule" pattern wherein psychological context ("set") is more strongly associated with psychedelic outcomes than substance type alone.
Neuropsychopharmacology January 16, 2026 Philip D. Harvey, Charles B. Nemeroff 2 citations
Interest in psychedelic therapies is booming, with hundreds of studies in process. Despite the interest, there are no approved psychedelic treatments for any psychiatric condition. Further, the one large-scale development program using MDMA that reached the FDA was disapproved by the agency for reasons that could apply to clinical trials for classical psychedelics. We review the definitions of...
PsyArXiv January 10, 2026 Jason B. Luoma, Jenna Lejeune, Brian Pilecki et al. preprint
The use of supportive touch in psychedelic-assisted therapy (PAT) and MDMA-assisted therapy (MDMA-AT) presents unique ethical challenges and opportunities. While touch can be a valuable component of treatment, its implementation requires careful consideration due to the altered states of consciousness induced by psychedelics and the potential for boundary violations. This paper addresses a...
Current Neuropharmacology January 9, 2026 Maria Antonietta De Luca, Cristina Miliano, Amanda Roxburgh et al. 1 citation
Preclinical and clinical studies reported that 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') can cause adverse effects in the central nervous system (CNS). Recently, preclinical studies have demonstrated that certain psychoactive substances may exacerbate the noxious central effects of MDMA when co-administered, including substances that are contained as adulterants in tablets sold as...
Psychedelics January 8, 2026 Rachel Yehuda, Amy Lehrner, Miryam Sperka et al. 2 citations
The original MAPS manual for MDMA-assisted therapy (MDMA-AT) opened a therapeutic frontier for PTSD. However, it drew critique for concepts—such as “inner healing intelligence” – that originated in transpersonal traditions rather than academic or empirically grounded clinical models. While many patients found the therapies helpful, these constructs were difficult to interpret and standardize....
Cureus 2026 Sebastian Hernandez Mejia, Aishwarya Ashwinee, Ranwa Aldaker
Rhabdomyolysis is a recognized complication of 3,4-methylenedioxymethamphetamine (MDMA), usually driven by severe hyperthermia and agitation. We describe a previously healthy 45-year-old man who developed profound rhabdomyolysis (creatine kinase (CK) 160,000 U/L) and intrinsic acute kidney injury requiring hemodialysis after ingesting 1.5 g of "Molly" (pure MDMA), despite remaining afebrile...
Case Reports in Psychiatry 2026 Ridhi J. Vyas, Ryan Hood, Jeremy Hsiang et al.
3,4‐Methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy (MDMA‐AP) has shown promise in treating post‐traumatic stress disorder (PTSD), particularly in treatment‐resistant cases. However, little is known about its potential to precipitate adverse psychiatric outcomes. We present the case of a 31‐year‐old woman with nondistressing childhood compulsions, chronic PTSD, and complex medical...